- Market Masters Daily
- Posts
- Ivonescimab Heating Up the Biotech Space
Ivonescimab Heating Up the Biotech Space
Get the hot trade we’re watching
*together with WealthMintr
Hey,
Free ‘pending’ biotech trade is on VERY close watch.
We’re talking about a trade that could soar 900% or better in the weeks ahead.
There’s tons of room on the horizon.
Why?
Ivonescimab: A next-generation cancer drug designed to attack tumors through 2 separate pathways at once.
Early trial success has already helped one biotech trade soar 900%+…
One breakthrough in biotech can change everything quickly.
P.S. Not only are you getting the hottest ‘pending’ biotech alert…
But you’re also getting 12 additional biotech alerts that look set to surge soon!
We worked diligently to make all of this possible for you.
All you need to do is take advantage while you can…
Questions or concerns about our products? Call 1-800-380-7072 or Email [email protected] © Copyright 2025, RagingBull.com, LLC
DISCLAIMER: To more fully understand any Ragingbull.com, LLC (RB) subscription, website, application or other service ("Services"), please review our full disclaimer located at https://ragingbull.com/disclaimer.
FOR EDUCATIONAL AND INFORMATION PURPOSES ONLY; NOT INVESTMENT ADVICE. Any RB Service offered is for educational and informational purposes only and should NOT be construed as a securities-related offer or solicitation, or be relied upon as personalized investment advice. RB strongly recommends you consult a licensed or registered professional before making any investment decision.
RESULTS PRESENTED NOT TYPICAL OR VERIFIED. RB Services may contain information regarding the historical trading performance of RB owners or employees, and/or testimonials of non-employees (including affiliates) depicting profitability that are believed to be true based on the representations of the persons voluntarily providing the testimonial. However, trading results of third parties may NOT have been tracked or verified and past performance is not necessarily indicative of future results, and the results presented in this communication are NOT guaranteed as TYPICAL. Actual results will vary widely given a variety of factors such as experience, skill, risk mitigation practices, market dynamics and the amount of capital deployed. Investing in securities is speculative and carries a high degree of risk; you may lose some, all, or possibly more than your original investment.
RAGINGBULL IS NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER. Neither RB nor any of its owners or employees is registered as a securities broker-dealer, broker, investment advisor(IA), or IA representative with the U.S. Securities and Exchange Commission, any state securities regulatory authority, or any self-regulatory organization.
WE MAY HOLD SECURITIES DISCUSSED. RB, its owners, and its employees may purchase, sell, or hold long or short positions in securities of the companies mentioned in this communication.
*AFFILIATE LINKS: If you purchase anything through a link in this email other than RB services, we earn a commission from the company providing that product. RB has affiliate relationships with these companies and receives compensation when you make purchases through our links. We recommend that you do your own independent research before purchasing anything. RB is not responsible for any content hosted on affiliate sites and it is the affiliate's responsibility to ensure compliance with applicable laws.
RB shall be entitled to recover attorneys' fees, costs and disbursements. In the event that any suit or action is instituted as a result of doing business with RB and/or its affiliates or if any suit or action is necessary to enforce or interpret these Terms of Service, RB shall be entitled to recover attorneys' fees, costs and disbursements in addition to any other relief to which it may be entitled.

